Genocea Biosciences, Inc.
GNCADelisted Jun 2, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001457612
Genocea Biosciences, Inc. was delisted on Jun 2, 2022; its insiders filed their last Form 4 on Jun 3, 2022; 40 institutions reported holding it in 13F filings for Q1 2022, worth $42.1M in total; no superinvestor held it.
Holders of 5% or more of GNCA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Genocea Biosciences, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Genocea Biosciences, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Genocea Biosciences, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2022 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Commodore Capital LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 20224:55 PM ET | GSK plc | 13G/AOld format | – | – | – | SEC |
| Apr 14, 2021 | New Enterprise Associates 16, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 31, 2021 | Commodore Capital LP | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | UBS Oconnor LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 20215:12 PM ET | GSK plc | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Vivo Opportunity, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Avoro Capital Advisors LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Genocea Biosciences, Inc. shares.
No Form 144 notices for Genocea Biosciences, Inc. are on file.